Aymen Al-Shamkhani

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Cancer Research Technology Limited, University of Southampton. Active years: 2013-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aymen Al-Shamkhani. Retrieved from https://idiyas.com/inventor/aymen-al-shamkhani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 46(Granted Patents)

Location History:

Otterbourne, GB (2013 - 2018)
Southampton, GB (2021 - 2023)

Company Filing History:

3 out of 268

Cancer Research Technology Limited

patents

3 out of 252

University of Southampton

patents

Years Active: 2013-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11780929 - Immunomodulatory antibodies (2023-10-10),

2. 11447549 - Combination of a Treg depleting anti-4-1BB antibody and anti-PD1 antibody (2022-09-20),

3. 11001638 - Immunomodulatory antibodies (2021-05-11),

4. 9926374 - Human immune therapies using a CD27 agonist in combination with another immune agonist to treat cancer (2018-03-27),

5. 9248183 - Human immune therapies using a CD27 agonist alone or in combination with other immune modulators (2016-02-02),

6. 8481029 - Human immune therapies using a CD27 agonist alone or in combination with other immune modulators (2013-07-09),

Title: Aymen Al-Shamkhani: Innovator in Immunotherapy

Introduction

Aymen Al-Shamkhani is a notable inventor based in Otterbourne, GB. He has made significant contributions to the field of immunotherapy, holding a total of 6 patents. His work focuses on developing innovative therapeutic methods that target cancer treatment.

Latest Patents

Among his latest patents, Al-Shamkhani has developed immunomodulatory antibodies that are specific for 4-1BB and OX40. These antibodies have potential therapeutic uses in various medical applications. Another significant patent involves the combination of a Treg depleting anti-4-1BB antibody and an anti-PD1 antibody. This invention describes a sequential administration method that enhances cancer treatment efficacy by utilizing both a Treg depleting antibody and an immunostimulatory antibody.

Career Highlights

Al-Shamkhani has worked with esteemed organizations such as the University of Southampton and Cancer Research Technology Limited. His career reflects a strong commitment to advancing cancer research and developing innovative treatment strategies.

Collaborations

He has collaborated with notable colleagues, including Martin John Glennie and Alison Louise Tutt, contributing to the advancement of immunotherapy research.

Conclusion

Aymen Al-Shamkhani's work in immunotherapy exemplifies the impact of innovative thinking in medical science. His patents and collaborations highlight his dedication to improving cancer treatment through groundbreaking research.

Profile summary based on public USPTO records.